Stock listing

BMV:GKOS Glaukos Corporation Acciones

Mexican listing (BMV) of Glaukos Corporation · home listing NYSE:GKOS

Follow Glaukos Corporation into a list and get an email when it puts out news.

Home listing price · NYSE:GKOS

$237.31 USD +4.23 (+1.8%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NYSE:GKOS

Past year +149.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$233.40 – $244.55 USDNov 20, 2026
Volume
1.09M sharesNov 20, 2026
Market cap
$14.05B USDAt the close on Nov 20, 2026 · price × 59.20M shares outstanding
52-week range
$93.78 – $255.19 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$234.7M USDMedian day 847,864 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Glaukos Corporation logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NYSE:GKOS · Home$237.31 USD+4.23 (+1.8%)1,089,498$238.87$244.55$233.40$233.08Close on Nov 20, 2026
Frankfurt:6GJ€214.00 EUR+6.00 (+2.9%)—€214.00€214.00€214.00€208.00Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NYSE:GKOS · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$237.31+4.23+1.8%$238.87$244.55$233.401,089,498
$233.08-10.17-4.2%$245.67$246.90$232.161,132,246
$243.25-1.63-0.7%$242.60$247.12$239.65718,354
$244.88-0.84-0.3%$245.43$250.61$242.01865,285
$245.72-0.31-0.1%$246.20$249.07$242.34546,413
$246.03-1.13-0.5%$248.03$249.97$242.66808,399
$247.16+10.97+4.6%$237.54$248.27$237.54915,543
$236.19-2.55-1.1%$237.94$241.35$235.09847,864
$238.74+14.33+6.4%$228.75$239.18$226.17853,912
$224.41+4.43+2.0%$221.51$229.05$219.061,202,800
$219.98-26.72-10.8%$250.00$250.40$218.772,042,190
$246.70+13.66+5.9%$237.18$255.19$235.272,080,947
$233.04-5.57-2.3%$240.94$240.94$230.0010,738,048
$238.61+1.01+0.4%$235.00$243.74$232.291,665,082
$237.60-4.88-2.0%$242.42$248.75$236.682,073,761
$242.48+61.05+33.6%$211.00$243.71$207.415,416,241
$181.43+0.26+0.1%$181.94$187.94$174.751,884,260
$181.17+2.90+1.6%$178.49$185.86$176.681,689,592
$178.27-0.61-0.3%$177.35$181.65$176.431,067,474
$178.88+2.19+1.2%$175.95$179.70$173.08961,189
$176.69-0.16-0.1%$176.72$178.22$174.21885,765
$176.85+3.42+2.0%$173.50$178.19$172.93930,333
$173.43+6.47+3.9%$168.00$176.07$168.00613,796
$166.96+2.12+1.3%$164.71$168.59$164.09775,393
$164.84-0.76-0.5%$166.08$167.28$163.131,032,231
$165.60-2.29-1.4%$168.26$170.20$165.36778,596
$167.89+2.39+1.4%$164.94$168.36$164.89624,166
$165.50-2.52-1.5%$169.53$171.22$164.95909,898
$168.02+2.33+1.4%$166.79$171.42$162.97881,892
$165.69+4.40+2.7%$160.06$166.97$159.891,196,008
$161.29-10.89-6.3%$170.67$170.86$146.392,899,156
$172.18+10.59+6.6%$161.00$174.48$159.591,487,661
$161.59-2.42-1.5%$163.84$164.00$160.30664,412
$164.01+0.26+0.2%$164.44$165.99$163.17837,810
$163.75+0.58+0.4%$167.57$168.08$163.01742,806
$163.17-1.02-0.6%$164.00$168.73$162.08808,411
$164.19+5.64+3.6%$158.31$165.65$157.29947,091
$158.55-0.010.0%$153.56$159.06$152.39638,201
$158.56+4.13+2.7%$153.11$160.98$151.711,400,531
$154.43-0.45-0.3%$154.50$155.60$151.01826,237
$154.88+1.39+0.9%$153.70$156.65$152.75838,399
$153.49-6.37-4.0%$159.86$162.04$153.311,026,755
$159.86-1.67-1.0%$165.36$165.36$159.001,102,409
$161.53-2.28-1.4%$166.27$166.74$160.23806,468
$163.81+2.39+1.5%$160.60$163.85$159.011,464,473
$161.42-2.05-1.3%$164.13$166.36$160.68646,798
$163.47-8.21-4.8%$172.01$173.55$162.12690,987
$171.68+0.59+0.3%$169.75$172.76$167.97621,746
$171.09+3.84+2.3%$168.51$171.36$165.43906,311
$167.25-3.13-1.8%$174.12$175.38$166.74552,413
$170.38-9.41-5.2%$176.50$179.96$169.261,009,478
$179.79-5.25-2.8%$183.15$183.33$178.52587,935
$185.04+7.57+4.3%$175.55$185.35$172.981,158,568
$177.47-2.88-1.6%$177.80$181.52$175.14572,538
$180.35+0.82+0.5%$180.80$181.30$178.72610,187
$179.53+2.83+1.6%$176.87$182.28$176.35768,719
$176.70-2.86-1.6%$179.97$180.14$175.33507,237
$179.56-0.31-0.2%$178.67$180.08$174.28455,572
$179.87-2.04-1.1%$181.10$182.23$177.77553,529
$181.91+1.34+0.7%$178.51$183.32$178.43442,313
$180.57-0.82-0.5%$180.11$181.89$176.82506,040
$181.39-4.26-2.3%$186.21$187.14$179.20639,693
$185.65+0.76+0.4%$184.13$186.88$181.75622,292
$184.890.000.0%$185.00$187.60$183.68440,096
$184.89-4.66-2.5%$187.73$191.62$183.25791,869
Ticker
BMV:GKOS
Asset type
Stock
Exchange
BMV
Currency
MXN

What changed lately

Latest news

All Glaukos Corporation news

Glaukos Corporation on 6ix

News releases
25 in the last 12 months · 43 in all · newest Nov 3, 2026 · oldest 2025
Calls
27 calls with a replay · 27 with a transcript · latest Oct 28, 2026
Decks
68 decks · latest Nov 6, 2026

Where Glaukos Corporation is listed

ListingExchangeCountryCurrency
NYSE:GKOS · Home listingNYSEUnited StatesUSD
gettex:6GJgettexGermanyEUR
LS Exchange:A14VCKLS ExchangeGermanyEUR
Lang & Schwarz:A14VCKLang & SchwarzGermanyEUR
BX Swiss:GKOSBX SwissSwitzerlandCHF
BOATS:GKOSBOATSUnited StatesUSD
Dusseldorf:6GJDusseldorfGermanyEUR
Frankfurt:6GJFrankfurtGermanyEUR
Munich:6GJMunichGermanyEUR
Stuttgart:6GJStuttgartGermanyEUR
Tradegate:6GJTradegateGermanyEUR
Xetra:6GJXetraGermanyEUR
BMV:GKOS · This pageBMVMexicoMXN

Valuation

Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$13.89B USD
P/E
Loss
EV/sales
20.1×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
19.6×
Gross margin
64.8%
Operating margin
−25.5%
Net margin
−24.6%
Debt to equity
0.0×
Beta vs S&P 500
0.87

Forecasts

9 strong buy · 3 buy · 1 hold · Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.

Price target
242.46 USD · Analysts' mean
EPS, year to Dec 2026
0.64 · 13 analysts
Revenue, year to Dec 2026
780.5M · 14 analysts

Team and board

Officers

OfficerRole
Thomas W. BurnsChairman & Chief Executive Officer
Alex R. ThurmanSenior Vice President, Chief Financial Officer
Joseph E. GilliamPresident & Chief Operating Officer
Paul BavierChief Legal Counsel
Robert L. DavisSenior Vice President, General Counsel & Business Development
Chris LewisVice President, Investor Relations & Corporate Affairs
Gabriella SzekelySenior Vice President, Research & Development, Combination Pharmaceutical Products
Matt YoungSenior Vice President, Global Operations
Michele M. AllegrettoSenior Vice President, Human Resources
Tracy M. FoundsSenior Vice President, Global Quality and Medical Safety
Jay L. KatzChief Medical Officer
Tomas NavratilChief Development Officer

Board

DirectorRole
Thomas W. BurnsChairman & Chief Executive Officer
Aimee S. WeisnerDirector
David F. HoffmeisterDirector
Denice M. TorresDirector
Gilbert H. KlimanDirector
Leana S. WenDirector
Marc A. StapleyDirector
Mark J. FoleyLead Independent Director

Events

Calls

CallWhenStatus
Glaukos (NYSE:GKOS) Q3 2026 Earnings CallWed, Oct 28, 2026 · 4:30 PM ETReplay
Glaukos (NYSE:GKOS) Q2 2026 Earnings CallWed, Jul 29, 2026 · 4:30 PM ETReplay
Glaukos (NYSE:GKOS) Q1 2026 Earnings CallWed, Apr 29, 2026 · 4:30 PM ETReplay
Glaukos (NYSE:GKOS) Q4 2025 Earnings CallTue, Feb 17, 2026 · 4:00 PM ETReplay
Glaukos (NYSE:GKOS) Q3 2025 Earnings CallWed, Oct 29, 2025 · 4:30 PM ETReplay
Glaukos (NYSE:GKOS) Q2 2025 Earnings CallWed, Jul 30, 2025 · 4:30 PM ETReplay
Glaukos (NYSE:GKOS) Q1 2025 Earnings CallWed, Apr 30, 2025 · 4:30 PM ETReplay
Glaukos (NYSE:GKOS) Q4 2024 Earnings CallThu, Feb 20, 2025 · 4:30 PM ETReplay
Glaukos (NYSE:GKOS) Q3 2024 Earnings CallMon, Nov 04, 2024 · 4:30 PM ETReplay
Glaukos (NYSE:GKOS) Q2 2024 Earnings CallWed, Jul 31, 2024 · 4:30 PM ETReplay
All 27 calls
CallWhenStatus
Glaukos (NYSE:GKOS) Q1 2024 Earnings CallWed, May 01, 2024 · 4:30 PM ETReplay
Glaukos (NYSE:GKOS) Q4 2023 Earnings CallWed, Feb 21, 2024 · 4:30 PM ETReplay
Glaukos (NYSE:GKOS) Q3 2023 Earnings CallWed, Nov 01, 2023 · 4:30 PM ETReplay
Glaukos (NYSE:GKOS) Q2 2023 Earnings CallWed, Aug 02, 2023 · 4:30 PM ETReplay
Glaukos (NYSE:GKOS) Q1 2023 Earnings CallWed, May 03, 2023 · 4:30 PM ETReplay
Glaukos (NYSE:GKOS) Q4 2022 Earnings CallWed, Feb 22, 2023 · 4:30 PM ETReplay
Glaukos (NYSE:GKOS) Q3 2022 Earnings CallWed, Nov 02, 2022 · 4:30 PM ETReplay
Glaukos (NYSE:GKOS) Q2 2022 Earnings CallWed, Aug 03, 2022 · 4:30 PM ETReplay
Glaukos (NYSE:GKOS) Q1 2022 Earnings CallWed, May 04, 2022 · 4:30 PM ETReplay
Glaukos (NYSE:GKOS) Q4 2021 Earnings CallTue, Feb 22, 2022 · 4:30 PM ETReplay
Glaukos (NYSE:GKOS) Q3 2021 Earnings CallThu, Nov 04, 2021 · 4:30 PM ETReplay
Glaukos (NYSE:GKOS) Q2 2021 Earnings CallThu, Aug 05, 2021 · 4:30 PM ETReplay
Glaukos (NYSE:GKOS) Q1 2021 Earnings CallWed, May 05, 2021 · 4:30 PM ETReplay
Glaukos (NYSE:GKOS) Q4 2020 Earnings CallThu, Feb 25, 2021 · 4:30 PM ETReplay
Glaukos (NYSE:GKOS) Q3 2020 Earnings CallThu, Nov 05, 2020 · 4:30 PM ETReplay
Glaukos (NYSE:GKOS) Q2 2020 Earnings CallThu, Aug 06, 2020 · 4:30 PM ETReplay
Glaukos (NYSE:GKOS) Q1 2020 Earnings CallThu, May 07, 2020 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Oct 28, 2026 · After close+33.6%
Q2 2026Jul 29, 2026 · After close+4.2%
Q1 2026Apr 29, 2026 · After close+22.8%
Q4 2025Feb 17, 2026+10.5%
Q3 2025Oct 29, 2025 · After close+13.9%
Q2 2025Jul 30, 2025 · After close−8.5%
Q1 2025Apr 30, 2025 · After close−11.4%
Q4 2024Feb 19, 2025 · Before open+5.0%
Q3 2024Nov 4, 2024 · After close−2.7%
Q2 2024Jul 31, 2024 · After close+0.4%
All 20 quarters
QuarterResultsShare move
Q1 2024May 1, 2024 · After close+6.2%
Q4 2023Feb 21, 2024 · After close−1.4%
Q3 2023Nov 1, 2023 · After close−7.6%
Q2 2023Aug 2, 2023 · After close−0.4%
Q1 2023May 3, 2023 · After close+8.8%
Q4 2022Feb 22, 2023 · After close−3.1%
Q3 2022Nov 2, 2022 · After close−9.6%
Q2 2022Aug 3, 2022 · After close+0.3%
Q1 2022May 4, 2022 · After close−5.5%
Q4 2021Feb 22, 2022 · After close+3.9%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck29 slidesNov 6, 2026
Q3 2026 Earnings PresentationEarnings7 slidesOct 28, 2026
Investor Presentation (August 2026)Investor deck28 slidesAug 3, 2026
Q2 2026 Earnings PresentationEarnings27 slidesJul 29, 2026
Q2 2026 Earnings PresentationEarnings28 slidesJul 29, 2026
Investor Presentation (May 2026)Investor deck28 slidesMay 4, 2026
Q1 2026 Earnings PresentationEarnings31 slidesApr 29, 2026
Q1 2026 Earnings PresentationEarnings28 slidesApr 29, 2026
Investor Presentation (March 2026)Investor deck28 slidesMar 2, 2026
FY2025 Earnings PresentationEarnings13 slidesFeb 17, 2026
Show 50 decks
DeckKindSlidesDate
Investor Presentation (January 2026)Investor deck28 slidesJanuary 2026
Investor Presentation (November 2025)Investor deck30 slidesNovember 2025
Q3 2025 Earnings PresentationEarnings26 slidesOct 29, 2025
Investor Presentation (August 2025)Investor deck29 slidesAugust 2025
Investor Presentation (May 2025)Investor deck29 slidesMay 2025
Investor Presentation (March 2025)Investor deck29 slidesMar 12, 2025
FY2024 Earnings PresentationEarnings13 slidesFeb 20, 2025
Investor Presentation (January 2025)Investor deck29 slidesJan 14, 2025
Investor Presentation (November 2024)Investor deck23 slidesNov 15, 2024
Q3 2024 Earnings PresentationEarnings25 slidesNov 4, 2024
Investor Presentation (August 2024)Investor deck23 slidesAug 9, 2024
Investor Presentation (May 2024)Investor deck23 slidesMay 2024
FY2023 Earnings PresentationEarnings16 slidesFeb 21, 2024
Investor Presentation (February 2024)Investor deck24 slidesFebruary 2024
Investor Presentation (January 2024)Investor deck24 slidesJanuary 2024
iDose TR FDA Approval Conference Call & Webcast (December 2023)Conference24 slidesDec 14, 2023
Investor Presentation (November 2023)Investor deck31 slidesNovember 2023
Q3 2023 Earnings PresentationEarnings10 slidesNov 1, 2023
Investor Presentation (August 2023)Investor deck31 slidesAugust 2023
Investor Presentation (May 2023)Investor deck31 slidesMay 17, 2023
Q1 2023 Earnings PresentationEarnings10 slidesMay 3, 2023
Investor Presentation (March 2023)Investor deck32 slidesMar 1, 2023
Investor Presentation (January 2023)Investor deck32 slidesJan 10, 2023
Investor Presentation (November 2022)Investor deck31 slidesNov 15, 2022
Q3 2022 Earnings PresentationEarnings7 slidesNov 2, 2022
Investor Presentation (September 2022)Investor deck31 slidesSep 7, 2022
Q2 2022 Earnings PresentationEarnings5 slidesAug 3, 2022
Investor Presentation (May 2022)Investor deck28 slidesMay 23, 2022
Q1 2022 Earnings PresentationEarnings4 slidesMay 4, 2022
Investor Presentation (March 2022)Investor deck28 slidesMar 2, 2022
Q4 2021 Earnings PresentationEarnings19 slidesFeb 22, 2022
Investor Presentation (January 2022)Investor deck28 slidesJan 11, 2022
Investor Presentation (November 2021)Investor deck28 slidesNov 22, 2021
Investor Presentation (August 2021)Investor deck28 slidesAug 18, 2021
Investor Presentation (March 2021)Investor deck29 slidesMar 4, 2021
Investor Presentation (January 2021)Investor deck27 slidesJan 13, 2021
Investor Presentation (November 2020)Investor deck28 slidesNov 10, 2020
Investor Presentation (May 2020)Investor deck27 slidesMay 11, 2020
Investor Presentation (March 2020)Investor deck27 slidesMar 6, 2020
Investor Presentation (January 2020)Investor deck27 slidesJan 15, 2020

This page holds 50 of 68 decks. Open Decks

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue507.4M383.5M314.7M282.9M294.0M225.0M237.0M181.3M159.3M114.4M
Cost of revenue111.8M94.0M75.6M69.0M66.6M91.7M38.6M25.1M21.1M16.2M
Gross profit282.8M289.5M239.1M213.9M227.4M133.2M198.4M156.2M138.2M98.2M
Research and development150.6M136.4M138.8M123.3M101.0M85.4M68.3M49.7M38.9M29.2M
Selling, general and administrative331.7M261.2M224.1M192.9M179.3M171.4M176.6M119.5M96.3M64.8M
Operating income-199.6M-122.4M-128.7M-82.3M-32.9M-123.6M-50.3M-13.0M-2.28M4.24M
Depreciation and amortization38.1M35.6M33.7M31.6M29.7M29.4M6.31M6.26M5.48M4.72M
EBITDA-161.5M-86.7M-95.0M-50.7M-3.21M-94.2M-44.0M-6.74M3.20M8.96M
Interest expense4.63M10.0M13.6M13.7M13.4M14.1M2.56M
Income before tax-193.0M-145.6M-133.7M-98.4M-49.3M-132.3M-50.0M-12.4M1.00K4.57M
Income tax-5.35M771.0K934.0K766.0K326.0K-12.0M-65.5M583.0K93.0K43.0K
Net income-187.7M-146.4M-134.7M-99.2M-49.6M-120.3M15.4M-13.0M-92.0K4.52M
Earnings per share, basic-3.28-2.77-2.78-2.09-1.07-2.700.41-0.370.000.14
Earnings per share, diluted-3.28-2.77-2.78-2.09-1.07-2.700.37-0.370.000.12

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents90.8M169.6M93.5M119.5M100.7M96.6M62.4M29.8M24.5M6.49M
Receivables108.6M60.7M39.9M36.1M33.4M36.1M38.4M18.7M16.7M14.3M
Inventory63.6M57.7M42.0M37.8M23.0M15.8M42.6M13.3M11.2M6.84M
Current assets475.0M449.8M395.5M443.9M486.1M469.4M262.9M176.6M149.5M120.0M
Property, plant and equipment113.3M97.9M103.2M94.4M69.0M24.0M22.1M19.2M11.8M7.59M
Goodwill66.7M66.1M66.1M66.1M66.1M66.1M66.1M
Total assets893.5M974.8M940.4M1.00B1.05B1.01B818.4M207.0M165.8M134.4M
Accounts payable24.6M13.0M13.4M14.4M7.33M4.37M5.78M6.29M6.24M2.97M
Current liabilities101.3M75.1M74.0M72.4M63.4M49.7M57.7M30.4M26.8M16.9M
Total liabilities237.3M207.8M478.6M472.4M462.5M338.1M145.1M33.1M27.6M17.1M
Shareholders' equity656.2M766.9M461.8M530.0M587.2M667.4M673.3M173.9M138.2M117.3M
Shares outstanding57.5M56.4M49.1M47.8M47.0M45.2M43.5M36.1M34.6M33.9M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-14.8M-61.3M-57.8M-33.1M24.7M-23.0M-369.0K18.9M26.1M12.3M
Capital spending-7.67M-6.30M-20.2M-30.3M-47.8M-6.93M-4.72M-10.3M-6.31M-6.28M
Free cash flow-22.5M-67.6M-78.0M-63.3M-23.1M-29.9M-5.09M8.55M19.8M6.03M
Cash from investing-77.6M47.8M14.1M44.8M-58.2M-205.1M43.4M-26.4M-12.4M-26.1M
Cash from financing11.9M91.5M15.0M6.25M39.3M262.5M-9.64M21.6M4.67M-1.64M
Change in cash-79.7M75.0M-27.3M16.5M3.96M34.4M33.2M14.1M17.9M-15.1M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 20, 2026Insider tradeSEC
4 · Change in ownershipNov 20, 2026Insider tradeSEC
4 · Change in ownershipNov 19, 2026Insider tradeSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
144 · Notice of proposed saleNov 18, 2026Other filingsSEC
144 · Notice of proposed saleNov 18, 2026Other filingsSEC
4 · Change in ownershipNov 16, 2026Insider tradeSEC
4 · Change in ownershipNov 16, 2026Insider tradeSEC
144 · Notice of proposed saleNov 16, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
144 · Notice of proposed saleNov 12, 2026Other filingsSEC
8-K · Current reportNov 6, 2026Current reportSEC
4 · Change in ownershipNov 5, 2026Insider tradeSEC
144 · Notice of proposed saleNov 4, 2026Other filingsSEC
4 · Change in ownershipNov 3, 2026Insider tradeSEC
4 · Change in ownershipNov 3, 2026Insider tradeSEC
4 · Change in ownershipNov 3, 2026Insider tradeSEC
144 · Notice of proposed saleOct 30, 2026Other filingsSEC
10-Q · Quarterly reportOct 28, 2026Quarterly reportSEC
8-K · Current reportOct 28, 2026ResultsSEC
4 · Change in ownershipOct 7, 2026Insider tradeSEC
144 · Notice of proposed saleOct 5, 2026Other filingsSEC
4 · Change in ownershipSep 28, 2026Insider tradeSEC
144 · Notice of proposed saleSep 25, 2026Other filingsSEC
4 · Change in ownershipSep 18, 2026Insider tradeSEC
144 · Notice of proposed saleSep 16, 2026Other filingsSEC
4 · Change in ownershipSep 1, 2026Insider tradeSEC
144 · Notice of proposed saleAug 28, 2026Other filingsSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
144 · Notice of proposed saleAug 19, 2026Other filingsSEC
4 · Change in ownershipAug 13, 2026Insider tradeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
144 · Notice of proposed saleAug 11, 2026Other filingsSEC
144 · Notice of proposed saleAug 7, 2026Other filingsSEC
4 · Change in ownershipAug 3, 2026Insider tradeSEC
8-K · Current reportAug 3, 2026Current reportSEC
144 · Notice of proposed saleJul 31, 2026Other filingsSEC
10-Q · Quarterly reportJul 29, 2026Quarterly reportSEC
8-K · Current reportJul 29, 2026ResultsSEC
4 · Change in ownershipJul 21, 2026Insider tradeSEC
144 · Notice of proposed saleJul 16, 2026Other filingsSEC
4 · Change in ownershipJul 13, 2026Insider tradeSEC
144 · Notice of proposed saleJul 9, 2026Other filingsSEC
4 · Change in ownershipJul 8, 2026Insider tradeSEC
4 · Change in ownershipJul 8, 2026Insider tradeSEC
144 · Notice of proposed saleJul 6, 2026Other filingsSEC
144 · Notice of proposed saleJul 1, 2026Other filingsSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4/A · Change in ownership, amendedJun 23, 2026Insider tradeSEC
4/A · Change in ownership, amendedJun 23, 2026Insider tradeSEC
4/A · Change in ownership, amendedJun 23, 2026Insider tradeSEC
4/A · Change in ownership, amendedJun 23, 2026Insider tradeSEC
4/A · Change in ownership, amendedJun 23, 2026Insider tradeSEC
4/A · Change in ownership, amendedJun 23, 2026Insider tradeSEC
4/A · Change in ownership, amendedJun 23, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
144 · Notice of proposed saleJun 16, 2026Other filingsSEC
8-K · Current reportJun 3, 2026Meeting outcomeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
SD · Specialized disclosureMay 29, 2026ESG reportSEC
4 · Change in ownershipMay 28, 2026Insider tradeSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
144 · Notice of proposed saleMay 14, 2026Other filingsSEC
4 · Change in ownershipMay 13, 2026Insider tradeSEC
144 · Notice of proposed saleMay 11, 2026Other filingsSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
8-K · Current reportMay 4, 2026Current reportSEC
144 · Notice of proposed saleMay 1, 2026Other filingsSEC
144 · Notice of proposed saleMay 1, 2026Other filingsSEC
144 · Notice of proposed saleApr 30, 2026Other filingsSEC
10-Q · Quarterly reportApr 29, 2026Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeApr 29, 2026Big-stake noticeSEC
8-K · Current reportApr 29, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeApr 29, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersApr 16, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 16, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 16, 2026Meeting noticeSEC
4 · Change in ownershipApr 14, 2026Insider tradeSEC
144 · Notice of proposed saleApr 10, 2026Other filingsSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
4 · Change in ownershipMar 27, 2026Insider tradeSEC
4 · Change in ownershipMar 27, 2026Insider tradeSEC
4 · Change in ownershipMar 27, 2026Insider tradeSEC
4 · Change in ownershipMar 27, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
4 · Change in ownershipMar 25, 2026Insider tradeSEC
4 · Change in ownershipMar 25, 2026Insider tradeSEC
4 · Change in ownershipMar 25, 2026Insider tradeSEC
4 · Change in ownershipMar 25, 2026Insider tradeSEC
144 · Notice of proposed saleMar 25, 2026Other filingsSEC
144 · Notice of proposed saleMar 24, 2026Other filingsSEC
4 · Change in ownershipMar 19, 2026Insider tradeSEC
4 · Change in ownershipMar 19, 2026Insider tradeSEC
4 · Change in ownershipMar 19, 2026Insider tradeSEC
4 · Change in ownershipMar 19, 2026Insider tradeSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
144 · Notice of proposed saleMar 17, 2026Other filingsSEC
144 · Notice of proposed saleMar 16, 2026Other filingsSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
8-K · Current reportMar 2, 2026Current reportSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
S-8 · Registration statement for employee plansFeb 24, 2026Offer documentSEC
4 · Change in ownershipFeb 23, 2026Insider tradeSEC
10-K · Annual reportFeb 20, 2026Annual reportSEC
144 · Notice of proposed saleFeb 19, 2026Other filingsSEC
8-K · Current reportFeb 17, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 11, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 10, 2026Big-stake noticeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 23, 2026Insider tradeSEC
144 · Notice of proposed saleJan 22, 2026Other filingsSEC
144 · Notice of proposed saleJan 22, 2026Other filingsSEC
144 · Notice of proposed saleJan 21, 2026Other filingsSEC
4 · Change in ownershipJan 20, 2026Insider tradeSEC
144 · Notice of proposed saleJan 16, 2026Other filingsSEC
8-K · Current reportJan 13, 2026ResultsSEC
144 · Notice of proposed saleJan 8, 2026Other filingsSEC
4 · Change in ownershipJan 7, 2026Insider tradeSEC
4 · Change in ownershipJan 7, 2026Insider tradeSEC
4 · Change in ownershipJan 7, 2026Insider tradeSEC
4 · Change in ownershipJan 7, 2026Insider tradeSEC
4 · Change in ownershipJan 7, 2026Insider tradeSEC
4 · Change in ownershipJan 7, 2026Insider tradeSEC
4 · Change in ownershipJan 7, 2026Insider tradeSEC
4 · Change in ownershipDec 31, 2025Insider tradeSEC
4 · Change in ownershipDec 31, 2025Insider tradeSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
144 · Notice of proposed saleDec 9, 2025Other filingsSEC
4 · Change in ownershipNov 26, 2025Insider tradeSEC
144 · Notice of proposed saleNov 25, 2025Other filingsSEC
4 · Change in ownershipNov 20, 2025Insider tradeSEC
144 · Notice of proposed saleNov 18, 2025Other filingsSEC
8-K · Current reportNov 10, 2025Current reportSEC
10-Q · Quarterly reportOct 30, 2025Quarterly reportSEC
8-K · Current reportOct 29, 2025ResultsSEC
4 · Change in ownershipSep 24, 2025Insider tradeSEC
4 · Change in ownershipSep 24, 2025Insider tradeSEC
4 · Change in ownershipSep 24, 2025Insider tradeSEC
4 · Change in ownershipSep 22, 2025Insider tradeSEC
4 · Change in ownershipSep 22, 2025Insider tradeSEC
4 · Change in ownershipSep 22, 2025Insider tradeSEC
144 · Notice of proposed saleSep 22, 2025Other filingsSEC
4 · Change in ownershipSep 12, 2025Insider tradeSEC
144 · Notice of proposed saleSep 11, 2025Other filingsSEC
S-8 · Registration statement for employee plansAug 20, 2025Offer documentSEC
SCHEDULE 13G · Big-stake noticeAug 12, 2025Big-stake noticeSEC
8-K · Current reportAug 12, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 7, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 4, 2025Quarterly reportSEC
8-K · Current reportJul 30, 2025ResultsSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
8-K · Current reportJun 3, 2025Meeting outcomeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipMay 30, 2025Insider tradeSEC
SD · Specialized disclosureMay 30, 2025ESG reportSEC
4 · Change in ownershipMay 28, 2025Insider tradeSEC
4 · Change in ownershipMay 28, 2025Insider tradeSEC
8-K · Current reportMay 14, 2025Current reportSEC
4 · Change in ownershipMay 9, 2025Insider tradeSEC
4 · Change in ownershipMay 9, 2025Insider tradeSEC
10-Q · Quarterly reportMay 1, 2025Quarterly reportSEC
8-K · Current reportApr 30, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 29, 2025Big-stake noticeSEC
4 · Change in ownershipApr 23, 2025Insider tradeSEC
4 · Change in ownershipApr 23, 2025Insider tradeSEC
ARS · Annual report to shareholdersApr 15, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 15, 2025Meeting noticeSEC

This page holds 200 of 1,005 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Glaukos Corporation’s releases · as of Oct 26, 2026

Common shares
59,196,870
Fully diluted
59,196,870

Fully diluted

LineSharesAs of
Common shares59,196,870Oct 26, 2026

Share count over time

CountShares
Oct 26, 202659,196,870

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
BlackRock9.32MUS$1.53BSep 30, 2026
Vanguard6.37MUS$1.05BSep 30, 2026
Janus Henderson4.63MUS$760MSep 30, 2026
Primecap Management Co3.08MUS$505MSep 30, 2026
Fidelity2.87MUS$471MSep 30, 2026
State Street2.31MUS$380MSep 30, 2026
Millennium1.46MUS$240MSep 30, 2026
Geode Capital1.45MUS$238MSep 30, 2026
Invesco1.24MUS$203MSep 30, 2026
Goldman Sachs1.03MUS$168MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Capital Group1.02MUS$167MSep 30, 2026
AllianceBernstein975KUS$160MSep 30, 2026
Holocene Advisors, LP849KUS$139MSep 30, 2026
Schwab807KUS$133MSep 30, 2026
Westfield Capital Management Co LP786KUS$129MSep 30, 2026
Arrowstreet Capital, Limited Partnership653KUS$107MSep 30, 2026
William Blair Investment Management, LLC651KUS$107MSep 30, 2026
Morgan Stanley620KUS$102MSep 30, 2026
Nomura617KUS$101MSep 30, 2026
Franklin Templeton612KUS$113MSep 30, 2026
T. Rowe Price601KUS$98.8MSep 30, 2026
Artisan Partners Limited Partnership600KUS$98.4MSep 30, 2026
Fuller & Thaler Asset Management, Inc.586KUS$96.2MSep 30, 2026
Northern Trust585KUS$96.1MSep 30, 2026
Bank of America581KUS$95.4MSep 30, 2026
Driehaus Capital Management LLC543KUS$89.2MSep 30, 2026
Summit Partners Public Asset Management, LLC532KUS$87.4MSep 30, 2026
Anomaly Capital Management, LP519KUS$85.3MSep 30, 2026
Loomis Sayles & Co L P493KUS$80.9MSep 30, 2026
UBS448KUS$73.6MSep 30, 2026
Wellington419KUS$68.9MSep 30, 2026
Lord, Abbett & Co. LLC412KUS$67.6MSep 30, 2026
Neuberger Berman Group LLC365KUS$59.9MSep 30, 2026
Vaughan Nelson Investment Management, L.P.364KUS$59.7MSep 30, 2026
BNY358KUS$58.7MSep 30, 2026
Allspring Global Investments Holdings, LLC347KUS$56.7MSep 30, 2026
Braidwell LP344KUS$56.5MSep 30, 2026
Citadel336KUS$55.1MSep 30, 2026
Principal318KUS$52.2MSep 30, 2026
Public Sector Pension Investment Board304KUS$50.9MSep 30, 2026
Nuveen275KUS$45.1MSep 30, 2026
Renaissance Technologies269KUS$44.1MSep 30, 2026
Jennison Associates LLC251KUS$41.1MSep 30, 2026
Alyeska Investment Group, L.P.239KUS$39.3MSep 30, 2026
Riverbridge Partners LLC223KUS$36.7MSep 30, 2026
Point72 Asset Management, L.P.202KUS$33.2MSep 30, 2026
Prudential Financial Inc197KUS$32.3MSep 30, 2026
Fred Alger Management, LLC190KUS$31.2MSep 30, 2026
JPMorgan177KUS$28.5MSep 30, 2026
BNP Paribas172KUS$28.3MSep 30, 2026

This page holds 50 of 409 holders. Open Shareholders

Funds

HolderSharesValueAs of
iShares Core S&P Small-Cap ETF3.54MUS$494MJun 30, 2026
Vanguard Total Stock Market Index Fund1.77MUS$248MJun 30, 2026
iShares Russell 2000 ETF1.48MUS$207MJun 30, 2026
Vanguard Capital Opportunity Fund1.48MUS$207MJun 30, 2026
Vanguard Small-Cap Index Fund1.28MUS$179MJun 30, 2026
Janus Henderson Triton Fund1.06MUS$148MJun 30, 2026
PRIMECAP Odyssey Aggressive Growth Fund1.01MUS$168MJul 31, 2026
SMALLCAP World Fund Inc989KUS$138MJun 30, 2026
Vanguard Small-Cap Growth Index Fund737KUS$103MJun 30, 2026
Janus Henderson Enterprise Fund709KUS$99MJun 30, 2026
Show 50 holders
HolderSharesValueAs of
Vanguard Extended Market Index Fund674KUS$94.2MJun 30, 2026
Janus Henderson Venture Fund672KUS$93.9MJun 30, 2026
Janus Henderson Contrarian Fund639KUS$89.3MJun 30, 2026
Fidelity Small Cap Index Fund630KUS$105MJul 31, 2026
Columbia Small Cap Growth Fund552KUS$57MMay 31, 2026
State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF539KUS$75.3MJun 30, 2026
iShares Russell 2000 Growth ETF532KUS$74.4MJun 30, 2026
Invesco Discovery Fund425KUS$43.9MMay 31, 2026
Nomura Small Cap Core Fund416KUS$43MMay 29, 2026
PRIMECAP Odyssey Growth Fund374KUS$62.3MJul 31, 2026
Vanguard Tax-Managed Small-Cap Fund373KUS$52.1MJun 30, 2026
iShares S&P Small-Cap 600 Growth ETF364KUS$50.9MJun 30, 2026
Vanguard Explorer Fund363KUS$60.5MJul 31, 2026
Fullerthaler Behavioral Small-Cap Growth355KUS$49.6MJun 30, 2026
Janus Henderson Global Select Fund323KUS$45.1MJun 30, 2026
Fidelity Extended Market Index Fund296KUS$30.6MMay 31, 2026
Vanguard Russell 2000 Index Fund287KUS$29.7MMay 31, 2026
AB Discovery Growth Fund, Inc.287KUS$40.1MJun 30, 2026
Columbia Acorn Fund284KUS$39.7MJun 30, 2026
Schwab U.S. Small-Cap ETF276KUS$28.5MMay 31, 2026
iShares U.S. Medical Devices ETF275KUS$38.4MJun 30, 2026
Fidelity Small Cap Growth Fund253KUS$42.1MJul 31, 2026
AB Small Cap Growth Portfolio244KUS$34.1MJun 30, 2026
State Street(R) SPDR(R) S & P 600(TM) Small Cap Growth ETF230KUS$32.1MJun 30, 2026
T. Rowe Price New Horizons Fund, Inc.204KUS$28.5MJun 30, 2026
Vanguard S&P Small-Cap 600 Index Fund199KUS$20.5MMay 31, 2026
Janus Henderson Global Life Sciences Fund197KUS$27.5MJun 30, 2026
Artisan International Small-Mid Fund191KUS$26.7MJun 30, 2026
PGIM Jennison Small Company Fund188KUS$26.3MJun 30, 2026
Fidelity Stock Selector Small Cap Fund186KUS$31.1MJul 31, 2026
Lord Abbett Developing Growth Fund Inc181KUS$30.1MJul 31, 2026
Vanguard Health Care Index Fund173KUS$17.8MMay 31, 2026
Lord Abbett Bond Debenture Fund Inc171KUS$23.9MJun 30, 2026
Loomis Sayles Small Cap Growth Fund157KUS$22MJun 30, 2026
iShares S&P Small-Cap 600 Value ETF157KUS$21.9MJun 30, 2026
Schwab U.S. Mid-Cap ETF155KUS$16.1MMay 31, 2026
Bridge Builder Small/Mid Cap Growth Fund149KUS$20.8MJun 30, 2026
Vaughan Nelson Small Cap Fund144KUS$20.2MJun 30, 2026
Eventide Healthcare & Life Sciences Fund143KUS$19.9MJun 30, 2026
Schwab Small-Cap Index Fund140KUS$23.4MJul 31, 2026

This page holds 50 of 418 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Thurman Alex R.
Officer: SVP & CHIEF FINANCIAL OFFICER
Sale132USD 241.49US$31,877Nov 18, 2026
Thurman Alex R.
Officer: SVP & CHIEF FINANCIAL OFFICER
Sale368USD 242.67US$89,303Nov 18, 2026
Thurman Alex R.
Officer: SVP & CHIEF FINANCIAL OFFICER
Sale998USD 243.91US$243KNov 18, 2026
Thurman Alex R.
Officer: SVP & CHIEF FINANCIAL OFFICER
Sale494USD 244.40US$121KNov 18, 2026
Thurman Alex R.
Officer: SVP & CHIEF FINANCIAL OFFICER
Sale268USD 246.12US$65,960Nov 18, 2026
Thurman Alex R.
Officer: SVP & CHIEF FINANCIAL OFFICER
Sale3,209USD 232.65US$747KNov 18, 2026
Thurman Alex R.
Officer: SVP & CHIEF FINANCIAL OFFICER
Sale1,493USD 233.62US$349KNov 18, 2026
Thurman Alex R.
Officer: SVP & CHIEF FINANCIAL OFFICER
Sale2,330USD 234.78US$547KNov 18, 2026
Thurman Alex R.
Officer: SVP & CHIEF FINANCIAL OFFICER
Sale548USD 235.50US$129KNov 18, 2026
Thurman Alex R.
Officer: SVP & CHIEF FINANCIAL OFFICER
Sale2,021USD 237.43US$480KNov 18, 2026
Show 50 trades
TradeTradeSharesPriceValueDate
Thurman Alex R.
Officer: SVP & CHIEF FINANCIAL OFFICER
Sale1,190USD 238.26US$284KNov 18, 2026
Thurman Alex R.
Officer: SVP & CHIEF FINANCIAL OFFICER
Sale826USD 239.52US$198KNov 18, 2026
Thurman Alex R.
Officer: SVP & CHIEF FINANCIAL OFFICER
Sale1,123USD 240.24US$270KNov 18, 2026
Gilliam Joseph E
Officer: PRESIDENT & COO
Sale861USD 250.00US$215KNov 16, 2026
Gilliam Joseph E
Officer: PRESIDENT & COO
Sale12,060USD 247.50US$2.98MNov 12, 2026
Gilliam Joseph E
Officer: PRESIDENT & COO
Sale300USD 248.42US$74,526Nov 12, 2026
Gilliam Joseph E
Officer: PRESIDENT & COO
Sale2,402USD 243.41US$585KNov 12, 2026
Gilliam Joseph E
Officer: PRESIDENT & COO
Sale3,700USD 244.49US$905KNov 12, 2026
Gilliam Joseph E
Officer: PRESIDENT & COO
Sale8,015USD 245.77US$1.97MNov 12, 2026
Gilliam Joseph E
Officer: PRESIDENT & COO
Sale18,440USD 246.49US$4.55MNov 12, 2026
Kliman Gilbert H
Director
Sale2,500USD 253.00US$633KNov 4, 2026
Navratil Tomas
Officer: CHIEF DEVELOPMENT OFFICER
Sale10,221USD 237.54US$2.43MOct 30, 2026
Navratil Tomas
Officer: CHIEF DEVELOPMENT OFFICER
Sale12,836USD 238.56US$3.06MOct 30, 2026
Navratil Tomas
Officer: CHIEF DEVELOPMENT OFFICER
Sale14,943USD 239.64US$3.58MOct 30, 2026
Navratil Tomas
Officer: CHIEF DEVELOPMENT OFFICER
Sale6,436USD 240.52US$1.55MOct 30, 2026
Navratil Tomas
Officer: CHIEF DEVELOPMENT OFFICER
Sale888USD 163.93US$146KOct 5, 2026
Navratil Tomas
Officer: CHIEF DEVELOPMENT OFFICER
Sale327USD 164.78US$53,883Oct 5, 2026
Navratil Tomas
Officer: CHIEF DEVELOPMENT OFFICER
Sale312USD 165.60US$51,667Oct 5, 2026
Navratil Tomas
Officer: CHIEF DEVELOPMENT OFFICER
Sale167USD 151.70US$25,334Sep 25, 2026
Navratil Tomas
Officer: CHIEF DEVELOPMENT OFFICER
Sale136USD 152.71US$20,769Sep 25, 2026
Navratil Tomas
Officer: CHIEF DEVELOPMENT OFFICER
Sale229USD 154.24US$35,321Sep 25, 2026
Navratil Tomas
Officer: CHIEF DEVELOPMENT OFFICER
Sale1,083USD 154.88US$168KSep 25, 2026
Navratil Tomas
Officer: CHIEF DEVELOPMENT OFFICER
Sale103USD 163.20US$16,810Sep 16, 2026
Navratil Tomas
Officer: CHIEF DEVELOPMENT OFFICER
Sale345USD 164.60US$56,787Sep 16, 2026
Navratil Tomas
Officer: CHIEF DEVELOPMENT OFFICER
Sale191USD 166.20US$31,744Sep 16, 2026
Navratil Tomas
Officer: CHIEF DEVELOPMENT OFFICER
Sale460USD 167.32US$76,967Sep 16, 2026
Navratil Tomas
Officer: CHIEF DEVELOPMENT OFFICER
Sale120USD 168.38US$20,206Sep 16, 2026
Navratil Tomas
Officer: CHIEF DEVELOPMENT OFFICER
Sale234USD 170.95US$40,002Sep 16, 2026
Navratil Tomas
Officer: CHIEF DEVELOPMENT OFFICER
Sale4USD 172.00US$688Sep 16, 2026
Navratil Tomas
Officer: CHIEF DEVELOPMENT OFFICER
Sale7,643USD 180.25US$1.38MAug 28, 2026
Navratil Tomas
Officer: CHIEF DEVELOPMENT OFFICER
Sale6,091USD 181.19US$1.1MAug 28, 2026
Navratil Tomas
Officer: CHIEF DEVELOPMENT OFFICER
Sale10USD 182.50US$1,825Aug 28, 2026
Kliman Gilbert H
Director
Sale2,500USD 190.00US$475KAug 19, 2026
Gilliam Joseph E
Officer: PRESIDENT & COO
Sale27,963USD 178.89US$5MAug 11, 2026
Gilliam Joseph E
Officer: PRESIDENT & COO
Sale32,037USD 180.49US$5.78MAug 11, 2026
Thurman Alex R.
Officer: SVP & CHIEF FINANCIAL OFFICER
Sale20,000USD 180.13US$3.6MAug 7, 2026
Wen Leana
Director
Sale525USD 167.63US$88,006Jul 31, 2026
Thurman Alex R.
Officer: SVP & CHIEF FINANCIAL OFFICER
Sale10,000USD 160.00US$1.6MJul 16, 2026
Thurman Alex R.
Officer: SVP & CHIEF FINANCIAL OFFICER
Sale10,000USD 155.00US$1.55MJul 9, 2026
Thurman Alex R.
Officer: SVP & CHIEF FINANCIAL OFFICER
Sale10,000USD 150.00US$1.5MJul 6, 2026

This page holds 50 of 61 trades. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
BlackRock, Inc.14.40%8.16MMar 31, 2025Schedule 13G
Janus Henderson Group PLC7.90%4.63MSep 30, 2026Schedule 13G
Primecap Management Co5.88%3.38MDec 31, 2025Schedule 13G
Vanguard Portfolio Management LLC5.60%3.26MMar 31, 2026Schedule 13G
Vanguard Capital Management LLC5.07%2.95MMar 31, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Samuel D Isaly
Other companies: Synlogic Inc (Director · Aug 28, 2017 – Aug 28, 2017 · Past); Alpine Immune Sciences Inc (Director · Jul 24, 2017 – Jul 24, 2017 · Past); Whitehawk Therapeutics, Inc. (Director · Mar 15, 2017 – Mar 15, 2017 · Past); Nabriva Therapeutics AG (Director · Dec 30, 2016 – Dec 30, 2016 · Past); Roka Bioscience Inc (Director · Sep 21, 2016 – Sep 21, 2016 · Past); Loxo Oncology Inc (Director · Aug 10, 2016 – Dec 8, 2017 · Past); Audentes Therapeutics Inc (Director · Jul 19, 2016 – Jul 19, 2016 · Past); Cartesian Therapeutics, Inc. (Director · Jun 21, 2016 – Jun 27, 2016 · Past); Corvus Pharmaceuticals, Inc. (Director · May 18, 2016 – Jun 23, 2016 · Past); Intellia Therapeutics, Inc. (Director · May 11, 2016 – May 11, 2016 · Past); Adaptimmune Therapeutics PLC (Director · Jan 1, 2016 – Mar 27, 2017 · Past); Otonomy Inc (Director · Nov 17, 2015 – Nov 25, 2015 · Past); Dimension Therapeutics (Director · Oct 27, 2015 – Oct 27, 2015 · Past); Sierra Oncology Inc (Director · Jul 15, 2015 – Jul 21, 2015 · Past); Palvella Therapeutics, Inc. (Director · Jun 29, 2015 – Jul 6, 2015 · Past); Intercept Pharmaceuticals Inc (Director · Apr 9, 2013 – Jul 17, 2015 · Past); Supernus Pharmaceuticals, Inc. (Director · May 4, 2012 – May 4, 2012 · Past); Anthera Pharmaceuticals Inc (Director · May 9, 2011 – Jan 30, 2013 · Past); Amarin Corporation plc (Director · Jan 1, 2011 – Sep 4, 2012 · Past); NxStage Medical Inc (Director · Jul 23, 2008 – Dec 9, 2010 · Past); Albireo Pharma Inc (Director · Feb 12, 2008 – Jun 9, 2009 · Past); Aryx Therapeutics Inc (Director · Nov 7, 2007 – Nov 13, 2007 · Past); Insulet Corporation (Director · May 14, 2007 – May 14, 2007 · Past); Volcano Corp (Director · Jun 14, 2006 – Jun 20, 2006 · Past); Given Imaging Ltd (Director · May 24, 2006 – May 24, 2006 · Past); Avanir Pharmaceuticals Inc (Director · Feb 13, 2006 – May 31, 2006 · Past)
Director · Jun 24, 2015 – Aug 31, 2017 · Past
William J. Link
Other companies: RxSight, Inc. (Director · Since at least Jul 29, 2021); Tarsus Pharmaceuticals, Inc. (Director · Since at least Oct 15, 2020); LENSAR, Inc. (Director · Since at least Sep 17, 2020); Oyster Point Pharma Inc (Director · Oct 30, 2019 – Jan 5, 2022 · Past); Vivani Medical, Inc. (Director · Nov 18, 2014 – Jun 4, 2019 · Past); Flexion Therapeutics Inc (Director · Sep 10, 2014 – Sep 10, 2014 · Past); Inogen, Inc (Director · Feb 12, 2014 – Feb 20, 2014 · Past); Edwards Lifesciences Corporation (Director · May 15, 2013 – May 8, 2020 · Past)
Director · Jun 24, 2015 – Jun 3, 2021 · Past
Denice Torres
Other companies: Seaport Therapeutics, Inc. (Board Member · Since at least Apr 30, 2026); Celldex Therapeutics, Inc. (Chief Executive Officer; The Ignited Company · Since at least Jun 5, 2025); 2Seventy Bio Inc (Director · Oct 18, 2021 – May 13, 2025 · Past); Surface Oncology Inc (Director · Jul 6, 2021 – Jun 8, 2022 · Past); Karuna Therapeutics Inc (Director · Dec 22, 2020 – Mar 18, 2024 · Past); Bluebird bio Inc (Director · Aug 10, 2020 – Nov 11, 2021 · Past)
Director · Since at least Mar 1, 2021
Aimee S. Weisner
Other companies: LENSAR, Inc. (Director · Since at least Feb 1, 2021); STAAR Surgical Company (Director · Jun 16, 2022 – Jun 20, 2024 · Past); Oyster Point Pharma Inc (Director · Oct 30, 2019 – Jan 3, 2023 · Past); Edwards Lifesciences Corporation (CVP, General Counsel · Jan 14, 2011 – May 9, 2012 · Past); Advanced Medical Optics Inc (EVP, Administration & Sec'y · May 24, 2006 – May 29, 2008 · Past)
Director · Since at least Jun 24, 2015
Gilbert H. Kliman
Other companies: Doximity, Inc. (Director · Jun 23, 2021 – Jul 27, 2022 · Past); STAAR Surgical Company (Director · Jun 1, 2020 – Dec 1, 2023 · Past); Venus Concept Inc (Director · Oct 11, 2017 – Nov 7, 2019 · Past); Epocrates Inc (Director · Feb 1, 2011 – Feb 1, 2011 · Past); Intralase Corp (Director · Jan 5, 2006 – Apr 2, 2007 · Past)
Director · Since at least Jun 24, 2015
Jonathan Silverstein
Other companies: Arcutis Biotherapeutics, Inc. (Director · Jan 30, 2020 – Oct 2, 2020 · Past); Adicet Bio, Inc. (Director · Jan 25, 2018 – Jun 3, 2020 · Past); Scpharmaceuticals Inc (Director · Nov 16, 2017 – Nov 21, 2017 · Past); Rhythm Pharmaceuticals, Inc. (Director · Oct 4, 2017 – Oct 4, 2017 · Past)
Director · Dec 13, 2017 – Mar 2, 2018 · Past
David F. Hoffmeister
Other companies: StepStone Group Inc. (Director · Since at least Sep 15, 2020); ICU Medical, Inc. (Independent Director · Since at least Jan 5, 2018); Celanese Corporation (Director · May 2, 2006 – May 9, 2025 · Past)
Director · Since at least Jun 24, 2015
Olav Bergheim
Other companies: Sonendo, Inc. (Director · Since at least Oct 28, 2021); Adagio Medical Holdings, Inc (CEO and Chairman, Director · Jul 31, 2024 – Jul 31, 2024 · Past); Volcano Corp (Director · Jun 14, 2006 – Aug 1, 2008 · Past)
Director · Jun 24, 2015 – Jul 23, 2015 · Past
Mark J. Foley
Other companies: SI-BONE, Inc. (Director · Jun 13, 2019 – Jun 16, 2020 · Past); Revance Therapeutics, Inc. (President & CEO, Director · Nov 7, 2017 – Feb 4, 2025 · Past)
Director · Since at least Dec 13, 2017
Paul S Madera
Other companies: Sonendo, Inc. (Director · Oct 28, 2021 – Nov 2, 2021 · Past); ForgeRock Inc (Director · Sep 15, 2021 – Mar 8, 2022 · Past)
Director · Jun 24, 2015 – Jun 30, 2015 · Past
All 28 people
PersonSeat
Robert More
Other companies: Tyra Biosciences, Inc. (Board Member · Since at least Sep 14, 2021); Vir Biotechnology, Inc. (Director · Since at least Oct 10, 2019)
Director · Jun 24, 2015 – Jun 30, 2015 · Past
Joseph E. Gilliam
Other companies: Caris Life Sciences, Inc. (Board Member · Since at least Jun 17, 2025)
President & Chief Operating Officer · Since at least May 5, 2017
Leana S. Wen
Other companies: UroGen Pharma Ltd. (Director · Since at least Sep 8, 2022)
Director · Since at least Mar 1, 2021
Marc A. Stapley
Other companies: Veracyte, Inc. (Chief Executive Officer, Director · Since at least Jun 1, 2021)
Director · Since at least May 30, 2019
Thomas W. Burns
Other companies: Pulmonx Corporation (Board Member · Since at least Sep 30, 2020)
Chairman & Chief Executive Officer · Since at least Jun 24, 2015
Alex R ThurmanSVP & CHIEF FINANCIAL OFFICER · Since at least Apr 1, 2022
Alex R. ThurmanSenior Vice President, Chief Financial Officer · Since at least Aug 11, 2026
Chris LewisVice President, Investor Relations & Corporate Affairs · Since at least Apr 16, 2026
Chris M CalcaterraChief Operating Officer · Jun 24, 2015 – Mar 24, 2022 · Past
Gabriella SzekelySenior Vice President, Research & Development, Combination Pharmaceutical Products · Since at least Nov 4, 2026
Jay L. KatzChief Medical Officer · Since at least Nov 4, 2026
Matt YoungSenior Vice President, Global Operations · Since at least Nov 4, 2026
Michele M. AllegrettoSenior Vice President, Human Resources · Since at least Nov 4, 2026
Paul BavierChief Legal Counsel · Since at least Dec 4, 2025
Richard L HarrisonCFO & Treasurer · Jun 24, 2015 – Jan 12, 2017 · Past
Robert L. DavisSenior Vice President, General Counsel & Business Development · Since at least Nov 4, 2026
Tomas NavratilCHIEF DEVELOPMENT OFFICER · Since at least Apr 1, 2022
Tracy M. FoundsSenior Vice President, Global Quality and Medical Safety · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Glaukos Corporation.